Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula

Stem Cells Translational Medicine

Volumn 4, Issue 5, 2015, Pages 532-537

  Cho, Yong Beom ^a   Park, Kyu Joo ^b   Yoon, Sang Nam ^c   Song, Kee Ho ^d   Kim, Do Sun ^d   Jung, Sang Hun ^e   Kim, Mihyung ^f   Jeong, Hee Young ^f   Yu, Chang Sik ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Daehang Hospital   (South Korea)

^e Yeungnam University Hospital   (South Korea)

^f Anterogen Co Ltd   (South Korea)

Author keywords

Adipose derived stem cells; Autologous stem cells; Complete closure of fistula; Crohn s fistula; Sustained response

Indexed keywords

INFLIXIMAB;

ABDOMINAL PAIN; ADIPOSE DERIVED STEM CELL; ADULT; ARTICLE; CLINICAL ARTICLE; CROHN FISTULA; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DISEASE DURATION; DISEASE EXACERBATION; ECZEMA; FEMALE; FEVER; HUMAN; HUMAN CELL; INJECTION; INTENTION TO TREAT ANALYSIS; MALE; PHASE 2 CLINICAL TRIAL; RETROSPECTIVE STUDY; SAFETY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; AUTOTRANSPLANTATION; BIOLOGICAL THERAPY; CROHN DISEASE; FISTULA; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; WOUND HEALING;

ADOLESCENT; ADULT; CELL- AND TISSUE-BASED THERAPY; CROHN DISEASE; FEMALE; FISTULA; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84930438990     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0199     Document Type: Article

References (40)

1. Maconi G, Bolzoni E, GiussaniAetal.Accu-racy and cost of diagnostic strategies for patients with suspected Crohn’s disease. J Crohn’s Colitis 2014;8:1684–1692.
2. Sangwan YP, Schoetz DJJr., Murray JJ et al. Perianal Crohn’s disease: Results of local surgical treatment. Dis Colon Rectum 1996;39: 529–535.
3. Sandborn WJ, Fazio VW, Feagan BG et al. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003;125:1508–1530.
4. Hwang SH, Bang MJ. Surgeryforacomplex anal fistula. J Korean Soc Coloproctol 2008;24: 77–82.
5. Gecse KB, Bemelman W, Kamm MA et al. A global consensusonthe classification, diagnosis and multidisciplinary treatment of perianal fis-tulising Crohn’s disease. Gut 2014;63: 1381–1392.
6. Parks AG, Stitz RW. The treatment of high fis-tula-in-ano. Dis Colon Rectum 1976;19:487–499.
7. Kodner IJ, Mazor A, Shemesh EI et al. Endorectal advancement flap repair of rectova-ginal and other complicated anorectal fistulas. Surgery 1993;114:682–689 discussion 689–690.
8. van Koperen PJ, Safiruddin F, Bemelman WA et al. Outcome of surgical treatment for fis-tulainanoinCrohn’s disease.BrJSurg 2009;96: 675–679.
9. Ritchie RD, Sackier JM, Hodde JP. Incontinence rates after cutting seton treatment for anal fistula. Colorectal Dis 2009;11:564–571.
10. Present DH. Crohn’s fistula: Current concepts in management. Gastroenterology 2003; 124:1629–1635.
11. Dejaco C, Harrer M, Waldhoer T et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther 2003;18:1113–1120.
12. Thia KT, Mahadevan U, Feagan BG et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: A randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009;15:17–24.
13. Pearson DC, May GR, Fick GH et al. Aza-thioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123:132–142.
14. Greenstein AJ, Kark AE, Dreiling DA. Crohn’s diseaseofthe colon:I.FistulainCrohn’s disease of the colon, classification presenting features and management in 63 patients. Am J Gastroenterol 1974;62:419–429.
15. Williams JG, MacLeod CA, Rothenberger DA et al. Seton treatment of high anal fistulae. Br J Surg 1991;78:1159–1161.
16. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistul-izing Crohn’s disease. N Engl J Med 2004;350: 876–885.
17. Levy C, Tremaine WJ. Management of internal fistulas in Crohn’s disease. Inflamm Bowel Dis 2002;8:106–111.
18. Liang J, Zhang H, Wang D et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut 2012;61:468–469.
19. Duijvestein M, Vos AC, Roelofs H et al. Autologous bone marrow-derived mesenchy-mal stromal cell treatment for refractory lumi-nal Crohn’s disease: Results of a phase I study. Gut 2010;59:1662–1669.
20. Ciccocioppo R, Bernardo ME, Sgarella A et al. Autologous bone marrow-derived mesen-chymal stromal cells inthe treatment of fistulis-ing Crohn’s disease. Gut 2011;60:788–798.
21. Cho YB, Lee WY, Park KJ et al. Autologous adipose tissue-derived stem cells for the treatment of Crohn’s fistula: A phase I clinical study. Cell Transplant 2013;22:279–285.
22. Lee WY, Park KJ, ChoYB et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells 2013;31:2575–2581.
23. Sciaudone G, Di Stazio C, Limongelli P et al. Treatment of complex perianal fistulas in Crohn disease: Infliximab, surgery or combined approach. Can J Surg 2010;53:299–304.
24. Tozer PJ, Burling D, Gupta A et al. Medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther 2011;33:5–22.
25. Van Assche G, Vanbeckevoort D, Bielen D et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003; 98:332–339.
26. Taxonera C, Schwartz DA, García-Olmo D. Emerging treatments for complex perianal fistula in Crohn’s disease. World J Gastroenterol 2009;15:4263–4272.
27. Garcia-Olmo D, Herreros D, Pascual I et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase II clinical trial. Dis Colon Rectum 2009; 52:79–86.
28. Guadalajara H, Herreros D, DeLaQuintana P et al. Long-term follow-upofpatients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis 2012;27:595–600.
29. Kim I, Lee SK, Yoon JI et al. Fibrin glue improves the therapeutic effectofMSCsbysus-taining survival and paracrine function. Tissue Eng Part A 2013;19:2373–2381.
30. Sotiropoulou PA, Perez SA, Salagianni M etal.Characterizationoftheoptimal culturecon-ditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006;24: 462–471.
31. Cholewa D, Stiehl T, Schellenberg A et al. Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant 2011;20: 1409–1422.
32. Salem HK, Thiemermann C. Mesenchy-mal stromal cells: Current understanding and clinical status. Stem Cells 2010;28:585–596.
33. Tsutsumi S, Shimazu A, Miyazaki K et al. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem Biophys Res Commun 2001;288:413–419.
34. Le Blanc K. Mesenchymal stromal cells: Tissue repair and immune modulation. Cyto-therapy 2006;8:559–561.
35. Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010;19:667–679.
36. Yoo KH, Jang IK, Lee MW et al. Comparison of immunomodulatory properties of mesenchy-mal stem cells derived from adult human tissues. Cell Immunol 2009;259:150–156.
37. Ge W, Jiang J, Arp J et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010;90:1312–1320.
38. Gonzalez-Rey E, Gonzalez MA, Varela N et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010; 69:241–248.
39. Batten P, Sarathchandra P, Antoniw JW et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: Relevance to tissue engineering human heart valves. Tissue Eng 2006;12:2263–2273.
40. González MA, Gonzalez-Rey E, Rico L et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gas-troenterology 2009;136:978–989.